An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma

Trial Profile

An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs APX 005M (Primary) ; NEO-PV 01 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Neon Therapeutics
  • Most Recent Events

    • 13 Jul 2018 Status changed from planning to not yet recruiting.
    • 27 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top